Komori
Nagaileben (7447) · TargetReframed

Sales of ¥18.6 billion and operating profit of ¥5.6 billion for the fiscal year ended August 2021

First written in FY2018. 7 of 15 entries say "Reframed", first in FY2021. Latest entry: 2026-10-02.

15entries
9years
3from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseReframedFY2019 – FY2023ReframedFY2025 – 2026-10-022018: 12019: 120192020: 120202021: 120212022: 120222023: 120232024: 420242025: 220252026: 32026
Same theme, other companies
Setting and achieving performance targets under the medium-term management planA theme 791 companies write about · 75 as a headwind · 1062 as a tailwind

The whole theme swung hardest in 2021: 17 of 77 companies on the "Worse" side.

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 133 companies compared. The sentences above are computed from all 133.Comparing 200 of the theme's 1182 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2025ReframedAnnual report

    「For the fiscal year ending August 2026, the Group targets revenue of ¥18.0 billion and operating profit of ¥4.025 billion. Under its medium-term management plan, it targets revenue of ¥19.5 billion and operating profit of ¥4.7 billion for the fiscal year ending August 2028.」

    The previous plans for the fiscal years ending August 2025 and August 2027 were updated, and targets were set for the fiscal years ending August 2026 and August 2028. The revenue target was raised, while the operating profit target was changed with the target date extended.
  2. FY2025-H1RestatedAnnual report

    「There were no material changes to the management policies, management strategies or other matters established by our Group during the interim consolidated accounting period.」

    The company states that there have been no significant changes to its management policies or management strategy, including its medium- to long-term plans.
  3. FY2024SoftenedAnnual report

    「For the fiscal year ending August 2025, the Group targets revenue of ¥17.5 billion and operating profit of ¥4.082 billion. Under its medium-term management plan, it targets revenue of ¥18.8 billion and operating profit of ¥4.8 billion for the fiscal year ending August 2027. To achieve these targets, it is pursuing market strategies including deepening its presence in core markets, expanding its share of peripheral markets and developing overseas markets; product strategies including the rollout of high-end, high-value-added products and the development of low-price strategic products using overseas materials and overseas factories; and production strategies including cost reductions through shifting production overseas, as well as the pursuit of domestic production, quick response and a wide range of products in small-lot production runs to enhance customer satisfaction.」

    The previous plans for the fiscal years ending August 2024 and August 2026 were updated, and targets were set for the fiscal years ending August 2025 and August 2027. Both the revenue and operating profit targets are lower than under the previous plans, and the use of low-price strategic products made with overseas materials and at overseas factories is explicitly identified as a new means of achieving them.
  4. FY2024-Q3RestatedAnnual report

    「There were no material changes during the nine-month consolidated period to the management policies, management strategies or other matters established by our group.」

    The company states that there have been no significant changes to its management policies or management strategy, including its medium- to long-term plans.
  5. FY2024-Q2RestatedAnnual report

    「There were no material changes to the Group’s management policies, management strategies or other related matters during the second quarter of the current fiscal year.」

    The company states that there have been no significant changes to its management policies or management strategy, including its medium- to long-term plans.
  6. FY2024-Q1AdvancedAnnual report

    「Under these circumstances, revenue for the cumulative first quarter of the consolidated fiscal year was ¥3,048 million, up 3.2% year on year, operating income was ¥657 million, up 4.3%, ordinary income was ¥676 million, up 4.3%, and quarterly net income attributable to owners of the parent was ¥464 million, up 4.2%.」

    Revenue in FY2024-Q1 increased 3.2% year on year, and the company reported higher revenue and operating profit as progress toward its FY2024 revenue target of ¥17.8 billion.
  7. FY2023ReframedAnnual report

    「For the fiscal year ending August 2024, the Group targets revenue of ¥17.8 billion and operating profit of ¥4.6 billion. Under its medium-term management plan, it targets revenue of ¥18.9 billion and operating profit of ¥5.5 billion for the fiscal year ending August 2026.」

    The plans for the fiscal years ending August 2023 and August 2025 presented in the previous fiscal year were updated, and new revenue and operating profit targets were set for the fiscal years ending August 2024 and August 2026.
  8. FY2022ReframedAnnual report

    「Our group has set revenue of ¥18.2 billion and operating profit of ¥4.5 billion for the fiscal year ending August 2023, and revenue of ¥19.3 billion and operating profit of ¥5.5 billion for the fiscal year ending August 2025 under its medium-term management plan.」

    The plan has been updated from the previous targets for the fiscal years ending August 2022 and August 2024 to new revenue and operating profit targets for the fiscal years ending August 2023 and August 2025.
  9. FY2021ReframedAnnual report

    「Our group has set revenue of ¥17.7 billion and operating profit of ¥5.0 billion for the fiscal year ending August 2022, and revenue of ¥18.5 billion and operating profit of ¥5.4 billion for the fiscal year ending August 2024 under its medium-term management plan. To achieve these targets, we will deepen our core market, expand our share in peripheral markets and develop overseas markets as market strategies; roll out high-end and high-value-added products as a product strategy; and reduce costs by shifting production overseas as a production strategy. We will also pursue domestic production QR and a diverse, low-volume product mix to increase customer satisfaction.」

    The company disclosed new numerical targets for the fiscal years ending August 2022 and August 2024, after having deemed calculation of numerical plans difficult in the previous fiscal year. Compared with the previous target for the fiscal year ending August 2022 of ¥18.4 billion in revenue and ¥5.6 billion in operating profit, the 2022 target was changed to ¥17.7 billion in revenue and ¥5.0 billion in operating profit, and a 2024 target was added.
  10. FY2020SoftenedAnnual report

    「Although the medium- to long-term impact of the novel coronavirus on the external environment is expected to make it difficult to calculate medium- to long-term numerical plans at this time, our business priorities for revenue are (1) expanding peripheral markets such as patient and surgical markets, (2) increasing our share in western Japan, (3) developing and selling high-end, high-value-added products, (4) developing infection-control products, and (5) developing overseas markets. For gross margin, the priorities are (1) pursuing a high-value-added strategy, (2) shifting production overseas, (3) minimizing foreign-exchange risk, and (4) transferring materials overseas.」

    Due to the impact of the novel coronavirus, the company deemed it difficult to calculate medium- to long-term numerical plans and disclosed only its business priorities without presenting its previous numerical targets.
  11. FY2019SoftenedAnnual report

    「As its medium- to long-term plan, our group has set revenue of ¥18.4 billion and operating profit of ¥5.6 billion for the fiscal year ending August 2022 as numerical targets.」

    The deadline has been extended from the previous fiscal year ending August 2021, with revenue of ¥18.6 billion and operating profit of ¥5.6 billion, to the fiscal year ending August 2022, and the revenue target has been lowered to ¥18.4 billion.
  12. FY2018First statedAnnual report

    「As its medium- to long-term plan, our group has set revenue of ¥18.6 billion and operating profit of ¥5.6 billion for the fiscal year ending August 2021 as numerical targets. To achieve them, our business priorities for revenue are (1) expanding peripheral markets such as patient and surgical markets, (2) increasing our share in western Japan, (3) developing and selling high-end, high-value-added products, and (4) developing overseas markets. For gross margin, the priorities are (1) pursuing a high-value-added strategy, (2) shifting production overseas, and (3) minimizing foreign-exchange risk.」

    The company has for the first time specified medium- to long-term numerical targets of ¥18.6 billion in revenue and ¥5.6 billion in operating profit by the fiscal year ending August 2021, along with the means of achieving them through peripheral markets, western Japan, high-value-added products, overseas markets, shifting production overseas and reducing foreign-exchange risk.
Moved together

"Rising Raw Material and Processing Costs" moved the same way as this thread, in the same document, in 8 of its 15 moves.

877665★123456
  1. ★This thread
  2. 1Rising Raw Material and Processing Costs8×
  3. 2Maintaining Gross Profit Margin at the Previous Year’s Level, with Revenue and Operating Profit Growth7×
  4. 3Uncertainty over the outlook for the domestic economy, personal consumption and exports7×
  5. 4Steady performance in healthcare wear and doctor wear, with growth in patient wear6×
  6. 5Revenue increased, while ordinary profit and net income declined6×
  7. 6The market environment for medical wear remains relatively stable5×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Nagaileben's next results are scheduled for 2026-10-01. Read the earnings preview It last moved in the Financial Results Presentation of 2026-10-02: "Reframed".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Sales of ¥18.6 billion and operating profit of ¥5.6 billion for the fiscal year ended August 2021 | NAGAILEBEN Co.,Ltd. (7447) | Komori